Health Economics, Pharmacoeconomics, Healthcare Policy, and Compliance

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/49

flashcard set

Earn XP

Description and Tags

Comprehensive practice flashcards covering health economics principles, pharmacoeconomic methodologies, healthcare delivery models, ACA provisions, and federal compliance regulations.

50 Terms

1
New cards

Health Economics

The discipline of economics applied to the topic of health care.

2
New cards

Economics

Broadly defined as how society allocates its resources among alternative uses.

3
New cards

2021 US Healthcare Spending

Increased 2.7%2.7\% to reach $4.3 trillion\$4.3\text{ trillion} (or $12,914\$12,914 per person), driven by a stronger economy, faster growth in medical prices, and an aging population.

4
New cards

US Healthcare System Ranking

Ranked 37th out of 191 national health care systems by the World Health Organization; as of 2022, ranked number 1 in spending but has the highest infant mortality, lowest life expectancy at birth, highest chronic condition rate, and highest avoidable death rate.

5
New cards

Health Care Costs

Expenses incurred or resources consumed in the provision of health care. In the US, there is no single source for obtaining costs and no single-payer system.

6
New cards

Direct Medical Costs

Costs of services or products associated directly with a medical condition or intervention, which can be fixed or variable and are the most common costs reported in pharmacoeconomic analyses (e.g., hospital charges).

7
New cards

Direct Non-Medical Costs

Costs of providing non-medical assistance associated with an intervention, such as food, lodging, and transport.

8
New cards

Indirect Costs

The cost of lost or reduced productivity resulting from morbidity or premature mortality due to a medical condition or intervention (e.g., inability to work due to illness).

9
New cards

Indirect Costs of Morbidity

Goods and services not produced by the patient because of illness.

10
New cards

Indirect Costs of Mortality

Goods and services the person could have produced had the illness not occurred and the person not died prematurely.

11
New cards

Intangible Costs

Costs assigned to the amount of suffering that occurs because of a disease or intervention, including pain, suffering, anxiety, and fatigue.

12
New cards

Cost Adjustment (Standardization)

Standardizing costs when they are estimated from data collected more than 1 year prior to the study so they are valued at a single point in time (e.g., adjusting 2010 costs to 2023 costs).

13
New cards

Discounting

Estimating costs based on dollars spent and saved in future years, valuing future health care savings at a lower rate than money today using a discount rate ranging from 3%3\% to 5%5\%.

14
New cards

Sensitivity Analysis

The process of altering assumptions in a pharmacoeconomic evaluation to determine whether the outcome remains the same; if it does not change, the study is considered robust.

15
New cards

Cost-Minimization Analysis (CMA)

A pharmacoeconomic evaluation that identifies cost differences between similar alternatives to select the least costly option when outcomes or consequences are shown to be identical.

16
New cards

Health-Related Quality of Life (HRQoL)

A patient's perception of their own health, distinct from general Quality of Life (QoL) which represents the overall perception of one's life.

17
New cards

Internal Consistency

An assessment of whether every test item within a scale measures the same construct, commonly quantified using Cronbach's α\alpha-coefficient.

18
New cards

Test–Retest Reliability

The relationship between scores obtained from administering the same instrument on two or more separate occasions.

19
New cards

Validity

The most important characteristic of a test; the degree to which an instrument actually measures what it is designed to measure, giving meaning to scores.

20
New cards

Quality-Adjusted Life Year (QALY)

A generic measure of disease burden that combines quality and quantity of life, where 1 QALY equates to one year lived in perfect health (Years of Life×Utility Value=#QALYs\text{Years of Life} \times \text{Utility Value} = \text{\#QALYs}).

21
New cards

Rating Scale (RS) / Visual Analogue Scale

A utility measurement method where 0=Dead0 = \text{Dead} and 100=Perfect health100 = \text{Perfect health}, and the respondent marks an 'X' corresponding to their preference for a health state.

22
New cards

Time Tradeoff (TTO)

A utility measurement method where subjects choose between living with a disease state for time tt versus living in perfect health for a shorter duration xx, calculated as Utility=xt\text{Utility} = \frac{x}{t}.

23
New cards

Standard Gamble (SG)

A utility measurement method offering a choice between the certainty of a chronic health state versus a gamble with two possible outcomes: immediate restoration of normal health or immediate death.

24
New cards

Cost-Effectiveness Analysis (CEA)

A pharmacoeconomic evaluation that measures costs in dollars and outcomes in natural health units to compare two or more treatments sharing a common clinical outcome.

25
New cards

Efficacy vs. Effectiveness

Efficacy measures how well an intervention works under experimental, controlled conditions (e.g., clinical trials); effectiveness measures how well it performs in real-world practice.

26
New cards

Incremental Cost-Effectiveness Ratio (ICER)

The preferred CEA metric revealing the additional cost per additional unit of effectiveness when switching treatments: ICER=Difference in CostDifference in EffectICER = \frac{\text{Difference in Cost}}{\text{Difference in Effect}}.

27
New cards

Cost-Benefit Analysis (CBA)

An evaluation measuring both costs and benefits entirely in monetary units; a program is justified if \frac{\text{Benefits } \}{\text{Cost } \} \ge 1 or if \text{Benefits } \ - \text{Cost } \>0> 0.

28
New cards

Decision Analysis (DA)

A quantitative analytical approach that models and systematically compares different decision options and their subsequent pathways and outcomes.

29
New cards

Decision Node

A point in a decision tree where several choices are available and the decision maker has direct control over which path is chosen.

30
New cards

Chance Node

A point in a decision tree where an uncertain event occurs and chance determines which outcome will happen.

31
New cards

Terminal Node

The end-point of a pathway in a decision tree representing the final outcome state for that sequence of events.

32
New cards

Essential Health Benefits (EHBs)

Ten core healthcare service categories required under the ACA, including ambulatory, emergency, hospitalization, lab, mental health/substance use, pediatrics (oral and vision, but excluding adult dental/vision), maternity/newborn, prescription drugs, preventive/wellness, and rehabilitative services.

33
New cards

King v. Burwell (2015)

The Supreme Court decision upholding that ACA tax subsidies were intended for individuals enrolled through any exchange program (including federal exchanges), securing the ACA's financial stability through 12/25.

34
New cards

Skilled Nursing Facility (SNF)

An institutional facility primarily engaged in providing skilled nursing care and rehabilitation services supervised by licensed RNs or practical nurses.

35
New cards

Assisted Living Facility

A custodial residential care setting providing 24-hour oversight, housekeeping, two meals per day, and personal assistance for individuals not requiring skilled nursing care (typical resident: female over 85 years of age).

36
New cards

Accountable Care Organization (ACO)

A network of healthcare providers jointly held accountable for achieving measured quality improvements and reductions in spending growth rate, typically requiring a 3-year commitment.

37
New cards

Patient-Centered Medical Home (PCMH)

A delivery model where a patient's care is coordinated comprehensively and holistically through their primary care physician to provide integrated access across extended providers.

38
New cards

Hospital Insurance and Diagnostics Service (HIDS) Act of 1957

Canadian legislation that established public insurance for universal inpatient hospital coverage across Canada.

39
New cards

Medical Care Act (MCA) of 1966

Canadian federal legislation that established the funding principles and framework for provincial Medicare coverage.

40
New cards

FDA Drug Development Phases

Preclinical (lab/animals); Phase I (safety, 20–80 individuals); Phase II (safety and effectiveness, 100–300 individuals); Phase III (effectiveness and adverse events, 1,000–3,000 individuals); Phase IV (post-marketing surveillance of long-term side effects).

41
New cards

Health Care Fraud

Knowingly submitting, or causing to be submitted, false claims or misrepresenting facts to obtain a federal health care payment when no entitlement exists.

42
New cards

Health Care Waste

The overuse of healthcare services or other practices that directly or indirectly cause unnecessary costs; represents a misuse of resources rather than criminal negligence.

43
New cards

Health Care Abuse

Practices inconsistent with sound medical, business, or fiscal standards that cause unnecessary costs, occurring without proof of the knowing misrepresentation required for fraud (e.g., upcoding or excessive supply billing).

44
New cards

Mandatory Exclusion

An OIG sanction requiring a minimum 5-year exclusion from billing any federal healthcare program following a conviction for program-related crimes, patient abuse/neglect, felony healthcare fraud, or felony controlled-substance violations.

45
New cards

List of Excluded Individuals/Entities (LEIE)

An OIG database of prohibited individuals and entities that healthcare providers must screen before hiring and on a monthly basis thereafter.

46
New cards

False Claims Act (FCA)

A federal statute prohibiting the knowing submission of false claims, false records, or withholding of overpayments ('reverse false claims'); violators face treble damages plus $14,308\$14,308 to $28,619\$28,619 per claim.

47
New cards

Anti-Kickback Statute (AKS)

A criminal law prohibiting knowingly and willfully offering, paying, soliciting, or receiving anything of value to induce or reward referrals for federally reimbursable healthcare business.

48
New cards

Stark Law

A strict-liability statute prohibiting physicians from referring Medicare patients for designated health services (including outpatient prescription drugs) to an entity with which they have a financial relationship, unless a specific statutory exception applies.

49
New cards

U.S. ex rel. Schutte v. SuperValu (2023)

A Supreme Court ruling establishing that False Claims Act knowledge focuses on what the defendant actually believed at the time of claim submission, not on after-the-fact reasonable interpretations.

50
New cards

CMS 60-Day Overpayment Rule

A rule mandating that healthcare providers report and return an identified overpayment within 60 days (with up to 180 days allowed for timely investigations); retaining overpayments past this period creates liability under the False Claims Act as a reverse false claim.